Dr. Jerry Silver: Trailblazing Spinal Cord Research

About this Video

• Video Title: Dr. Jerry Silver: Trailblazing Spinal Cord Research
• Channel: Guy Kawasaki
• Speakers: Guy Kawasaki, Jerry Silver
• Duration: 01:16:40

Introduction

This video features an interview with Dr. Jerry Silver, a neuroscientist, discussing his groundbreaking research on spinal cord injury treatments. The main focus is on the development and upcoming Phase 1B/2A clinical trials of NVG291, a peptide designed to promote nerve regeneration after spinal cord injury. The conversation traces Dr. Silver's research journey, spanning four decades, from his initial work on nerve cell growth in the eye to the current human trials.

Key Takeaways

• Phase 1B/2A of NVG291 Trials: The drug has shown safety in healthy individuals and is ready for trials in spinal cord injury patients. The trials will involve approximately 20 patients and will assess safety and efficacy through neurological exams and physiological measurements.
• Mechanism of NVG291: The peptide targets a receptor (PTP Sigma) on damaged nerve fibers that contributes to the formation of scar tissue, inhibiting regeneration. By blocking this receptor, the peptide promotes nerve regrowth. The peptide is administered subcutaneously, avoiding direct injection into the spinal cord.
• Long-term treatment potential: The treatment might continue for months or years if patients show improvement and no side effects. Rehabilitation programs would likely be integrated.
• Research Journey: Dr. Silver's research began with studying nerve growth in the eye, leading to the discovery of barrier molecules that inhibit nerve regeneration. This foundational work informed his later research on spinal cord injury.
• Fortunate Accident: A delayed study of rats with spinal cord injuries revealed that significant improvements occurred after a significantly longer period than initially anticipated, highlighting the potential for effective treatment even with chronic injuries.